Disease · EFO_0000556
ischemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. ischemia. Diseases, record EFO_0000556. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0000556
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CLOPIDOGREL BISULFATE | CHEMBL1083385 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANGRELOR | CHEMBL334966 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IXMYELOCEL-T | CHEMBL2108733 | Cell | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROSUVASTATIN | CHEMBL1496 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TREPROSTINIL SODIUM | CHEMBL561157 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DISUFENTON SODIUM | CHEMBL2107334 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets63
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | 4 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator | Approval | https://conductscience.org/library/genes/64805 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PTGIR | Prostacyclin receptor | 2 | Prostanoid IP receptor agonist | Phase 3 | https://conductscience.org/library/genes/5739 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 1 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/140 | Drugs and targets |
| F10 | Coagulation factor X | 1 | Coagulation factor X inhibitor | Phase 3 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
1 to 10 of 63
See all 63 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00385138 | Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. | Phase 3 | 5,364 | 2014-04-21 | Atherosclerosis, Acute Coronary Syndrome (ACS) | CANGRELOR, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT02091921 | Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study | Phase 1/2 | 53 | 2019-06-19 | Critical Limb Ischemia | TICAGRELOR | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01064440 | Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia | Phase 2 | 52 | 2024-09-19 | Critical Limb Ischemia | DONAPERMINOGENE SELTOPLASMID | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01309802 | A Two-Part Study of BOTOX® Therapy for Ischemic Digits | Phase 2 | 48 | 2017-06-02 | Raynaud's Disease | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT01585402 | Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) | Phase 2 | 7 | 2022-10-04 | Arterial Calcification, CD73 Deficiency | ETIDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00369356 | Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis | Phase 2/3 | 375 | Coronary Artery Disease, Ischemic Heart Disease, Atherosclerosis | PREDNISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00657527 | Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease | Phase 3 | 280 | Myocardial Ischaemia, Coronary Artery Disease | ROSUVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00379418 | Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients | 220 | Coronary Artery Disease | ABCIXIMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT04229264 | Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients. | Phase 3 | 200 | Critical Limb Ischemia | APIXABAN, ASPIRIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT02681913 | Adenosine as an Adjunct to Blood Cardioplegia | Phase 2 | 100 | Pathological Processes, Cardiomyopathies | ADENOSINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding | 145 of 2,662 | 91 of 2,650 | 5,312 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major | 4 of 2,662 | 9 of 2,650 | 5,312 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of GUSTO Severe / Life-threatening | 9 of 2,662 | 6 of 2,650 | 5,312 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm | 43 of 2,662 | 29 of 2,650 | 5,312 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: serious adverse events | 48 of 2,662 | 55 of 2,650 | 5,312 | NCT00385138 | Trial comparisons |
Cangrelor vs Clopidogrel: Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis] | 122 of 2,656 | 142 of 2,645 | 5,301 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis | 5 of 2,654 | 16 of 2,641 | 5,295 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI | 180 of 2,654 | 204 of 2,641 | 5,295 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of MI | 177 of 2,654 | 191 of 2,641 | 5,295 | NCT00385138 | Trial comparisons |
| Cangrelor vs Clopidogrel: Incidence of Stroke | 7 of 2,654 | 5 of 2,641 | 5,295 | NCT00385138 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials17
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 21531233 | RESULT | 1 | PubMed |
| 19915222 | RESULT | 1 | PubMed |
| 38568107 | DERIVED | 1 | PubMed |
| 38551015 | DERIVED | 1 | PubMed |
| 38326858 | DERIVED | 1 | PubMed |
| 35802393 | DERIVED | 1 | PubMed |
| 35196863 | DERIVED | 1 | PubMed |
| 33579317 | DERIVED | 1 | PubMed |
| 32730905 | DERIVED | 1 | PubMed |
| 29632238 | DERIVED | 1 | PubMed |
1 to 10 of 17
See all 17 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0000556
GET https://conductscience.org/api/diseases/v1/EFO_0000556/drugs?page=2